Targeted therapy response in early versus late recurrence of renal cell carcinoma after surgical treatment: A propensity score‐matched study using the Korean Renal Cancer Study Group database

Author(s):  
Chan Ho Lee ◽  
Jinsoo Chung ◽  
Cheol Kwak ◽  
Chang Wook Jeong ◽  
Seong Il Seo ◽  
...  
2018 ◽  
Vol 14 (2) ◽  
pp. 68-78 ◽  
Author(s):  
B. Ya. Alekseev ◽  
I. M. Shevchuk ◽  
A. D. Kaprin

Renal cell carcinoma (RCC) is one of the most common genitourinary malignancies worldwide. Approximately 25–30 % of newly diagnosed patients have metastatic RCC (mRCC), whereas in 20–30 % of cases, dissemination occurs after radical surgical treatment. The development of targeted and immunooncological agents in recent years significantly increased survival in patients with mRCC. However, clinicians faced a problem of choosing an optimal therapeutic regimen to achieve maximum effectiveness of the treatment. This article discusses the choice of second-line drugs for mRCC, advantages of axitinib and its optimal dosage, and efficacy of sunitinib depending on the disease prognosis.


2014 ◽  
Vol 13 (1) ◽  
pp. e199
Author(s):  
I. Peters ◽  
N. Dubrowinskaja ◽  
M. Abbas ◽  
C. Seidel ◽  
M. Kogosov ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document